NaMuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic (NDM) disorders.1
NaMuscla is the first licensed antimyotonic demonstrated to:
• Control symptoms of myotonia in adult patients with NDM.1,2
• Improve patient’s daily lives.1,2
• Provide generally well-tolerated, long-term myotonia relief.3
Myotonia is more than an inability to relax muscles.4,5
Myotonia is a chronic, lifelong condition that impacts NDM patients on a daily basis.4,5
Untreated myotonia can have dramatic consequences for NDM patients.
Myotonia restricts everyday life.
Demonstrated effective relief from NDM-related myotonia.1,2
Long-term experience in patients with NDM – retrospective chart review (4.8y).3
NaMuscla composition & dosing.1
Each patient should be given a Patient Alert card before initiating treatment with NaMuscla®
Healthcare Professional Education Guide and Patient Alert cards are available from: www.medicines.org.uk
References: 1. NaMuscla Summary of Product Characteristics. Lupin Europe GmbH. 2. Vicart S, et al. Neuromuscular Disorders 2021; 31(11):1124-1135. 3. Suetterlin KJ, et al. JAMA Neurology 2015; 72(12):1531-1533. 4. Trivedi JR, et al. Brain 2013; 136:2189-2200. 5. Trip J, et al. J Neurol 2009; 256:939-947. 6. Statland JM, et al. JAMA 2012; 308:(13):1357-1365.
Product details
